Global Investor News March 2022
DATE: Tuesday 11th January 2022
Author: Dr. Sean Hall,
From our CEO
Firstly welcome. In a new initiative designed to provide greater and more meaningful communication with our investment communities, it gives me great pleasure to share this bi-monthly, news article.
Looking back at the past few months and continually thinking about our forward plans, I am happy with the fundamentals of the business. Our principle asset in the delivery platform is globally protected, our drug development programs continue to progress and our partnering endeavours are stronger than ever.
I am reminded of GW Pharmaceuticals (GWPH), relatively unknown until they scored FDA approval on one product (and that was after a failure), but became topical in May last year when they were acquired by Jazz Pharmaceuticals.
Like all biotech’s, GW Pharma (GWPH) was not an overnight success, many years went into evolving their drug development product and securing their assets before any meaningful revenue was forthcoming. Similar can be said with a now household pharmaceutical name, Moderna.
Medlab is no different, we continue to evolve and strengthen our drug development work, we protect our assets and we look for meaningful, long-term, strategic partners.
Morgans provide updated guidance
Medlab Clinical (MDC)
All eyes on licensing deal flow to fund major program
SPECULATIVE BUY (maintained) | Target price: A$0.30 (previous: A$0.29) | Current price: A$0.135
- MDC released its 1H22 results which were broadly in-line with our forecasts on a continued operations basis.
- Major change in the period was the divestment of the Australian nutraceuticals business. MDC anticipates OPEX savings of ~A$2.0m pa.
- Looking forward, the core focus surrounds its drug delivery and development, accelerating news flow around partnering discussions for its two major assets, and advancing preparatory works for its Ph3 cancer pain trial.
- The size, timing, and shape of these deals will be absolutely key ahead of advancing its major cancer pain asset with clinical expenditure estimates currently well in excess of cash balance.
- Our valuation and price target increases marginally to A$0.30 (from A$0.29) and we retain a Speculative Buy recommendation.
UK entry for NanaBis™ and NanoCBD ™
We have previously announced both NanoCBD™ and NanaBis™ are entering the UK compassionate space.
After the CEO’s last visit to London, applications for our first lot of importation and use have been made to various UK departments. Dr. Hall said he feels encouraged by those UK doctors and patients wishing to support the program.
The UK compassionate use space is quite different to the Australian space, but like the Australian space allows for early revenue and key opinion leader development.
This initiative is underway now, with the next step awaiting UK approvals to fulfil script requests.
About the author
Dr. Sean Hall
Sean founded Medlab in August 2012; he has over 20 years' experience in nutraceutical sales and development, as well as early drug discovery in Australia, Asia and the US. Sean has led and inspired his teams to author multiple patents, write peer-reviewed articles and deliver lectures at scientific conferences. His passion is leading his researchers into novel areas and strong commercialisation opportunities.
Prior Sean was a founder of FIT-BioCeuticals. Under his management and guidance, BioCeuticals became the most innovative, research-driven, practitioner brand in Australia. For his sale of FIT-BioCeuticals to Blackmores in 2012, Sean was nominated as a finalist in the inaugural Australian Exit CEO of the Year Award. Sean is a Medical Doctor with an MBA in clinical pharmaceutical management and focuses on the research to pioneer innovation and commercialisation. Sean is an active member of Medicines Australia, the European Medical Association, the American Federation for Medical Researcher, The World Medical Association, A4M and Special Operations Medical Association.